Rilzabrutinib effective and safe against chronic spontaneous urticaria, finds study

A recent study published in the Journal of Allergy and Clinical Immunology unveiled promising results from a Phase 2 study evaluating the efficacy and safety of rilzabrutinib (SAR444671) in addressing Chronic Spontaneous Urticaria (CSU). CSU is a distressing skin condition often resistant to conventional treatments, is characterized by recurring hives and intense itching, significantly impacting quality of life of the patients.

The RILECSU study encompassed a 52-week investigation involving adults with moderate-to-severe CSU that is inadequately managed by H1 antihistamine treatment alone. The study comprised a 12-week randomized, double-blind, placebo-controlled, dose-ranging phase that was succeeded by a 40-week open-label extension period.

The participants (N=160) were randomly assigned to receive rilzabrutinib at varying doses or a matching placebo. The individuals who were administered with rilzabrutinib at 400mg three times a day (TID) demonstrated significant improvements when compared to the placebo group. A marked reduction in weekly Itch Severity Score (ISS7) and Urticaria Activity Score (UAS7) was observed as early as Week 1, with sustained efficacy through Week 12.

Also, rilzabrutinib expressed a favorable safety profile, with adverse events that ranged from headache, nausea to diarrhea occurring at a higher frequency but remaining manageable. These findings highlight the potential of rilzabrutinib as a promising therapeutic option for the individuals  with the debilitating effects of CSU.

This study emphasized the significance of rilzabrutinib’s rapid onset and tolerability in addressing the unmet needs of CSU patients. The results pave the way for further exploration into the efficacy of rilzabrutinib across diverse patient populations and reinforce the importance of continued research in advancing treatment modalities for chronic skin diseases.

Source:

Maurer, M., Gimenez-Arnau, A., Ferrucci, S., Mikol, V., Sun, I., Mannent, L., & Gereige, J. (2024). Efficacy and Safety of Rilzabrutinib in Patients With Chronic Spontaneous Urticaria: 12-Week Results From the RILECSU Phase 2 Dose-Ranging Study. In Journal of Allergy and Clinical Immunology (Vol. 153, Issue 2, p. AB373). Elsevier BV. https://doi.org/10.1016/j.jaci.2023.11.893

Powered by WPeMatico

Once-weekly survodutide safely tied to substantial weight loss in obese individuals: Study

Germany: In adults with a BMI of 27 kg/m2 or greater without diabetes, once-weekly survodutide produced significant reductions in body weight versus placebo from baseline to week 46, findings from a recent phase 2 trial have revealed. Survodutide’s tolerability profile was in line with what would be expected based on its mechanism of action; participants most frequently reported gastrointestinal adverse events.

“All tested survodutide doses significantly reduced body weight in a dose-dependent manner relative to placebo in participants with a BMI of 27 kg/m2 or greater (0·6 mg, ≥2·4 mg),” the researchers reported in their study published in The Lancet Diabetes & Endocrinology.

Survodutide doses 2·4 mg or higher resulted in substantial, clinically relevant bodyweight losses of 5% or more in over half of the participants within 8 weeks of treatment initiation.

Obesity is a chronic and widespread condition that requires long-term management, research into additional targets to improve treatment outcomes remains a priority. Therefore, Anita M Hennige, Boehringer Ingelheim International GmbH, Biberach an der Riß, Germany, and colleagues aimed to investigate the efficacy, safety, and tolerability of glucagon receptor–GLP-1 receptor dual agonist survodutide (BI 456906) in obesity management.

For this purpose, the researchers conducted a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial in 43 centres in 12 countries. Participants aged 18–75 years, BMI ≥27 kg/m2, and without diabetes were enrolled. They were randomly assigned in a ratio of 1:1:1:1:1 to subcutaneous survodutide (0·6, 2·4, 3·6, or 4·8 mg) or placebo once-weekly for 46 weeks (20 weeks dose escalation; 26 weeks dose maintenance).

The study’s primary endpoint was the percentage change in weight from baseline to week 46. The primary analysis included the modified intention-to-treat population and was based on the dose assigned at randomisation (planned treatment), containing all data censored for COVID-19-related discontinuation. The modified intention-to-treat population was defined as all randomly assigned patients who received at least one dose of trial medication and who had analysable data for at least one efficacy endpoint.

The sensitivity analysis was based on the actual dose received during the maintenance phase (actual treatment) and included on-treatment data. The safety analysis included all the participants who received at least one dose of the study drug.

387 participants were enrolled between March 30, 2021, and Nov 11, 2021; 386 participants were treated (0·6 mg, n=77; 2·4 mg, n=78; 3·6 mg, n=77; 4·8 mg, n=77; placebo n=77) and 233 of 386 completed the 46-week treatment period (187 of 309 receiving survodutide; 46 of 77 receiving placebo).

Based on the study, the researchers reported the following findings:

  • When analysed according to planned treatment, mean changes in body weight from baseline to week 46 were −6·2%; −12·5%; −13·2%; −14·9%; −2·8%.
  • Adverse events occurred in 91% of 309 survodutide recipients and 75% of 77 placebo recipients; these were primarily gastrointestinal in 75% of 309 survodutide recipients and 42% of 77 placebo recipients.

“All tested survodutide doses were tolerated, and dose-dependently reduced body weight,” the researchers wrote. The effect of survodutide on body weight was sustained throughout the treatment period.

Reference:

Le Roux, C. W., Steen, O., Lucas, K. J., Startseva, E., Unseld, A., & Hennige, A. M. (2024). Glucagon and GLP-1 receptor dual agonist survodutide for obesity: A randomised, double-blind, placebo-controlled, dose-finding phase 2 trial. The Lancet Diabetes & Endocrinology, 12(3), 162-173. https://doi.org/10.1016/S2213-8587(23)00356-X

Powered by WPeMatico

Investigational oral drug sebetralstat provided on-demand relief during tissue swelling attacks from hereditary angioedema: Phase 3 study

USA: A phase III study showed that an investigational oral drug sebetralstat provided on-demand relief during tissue swelling attacks from hereditary angioedema (HAE).

KONFIDENT is the first phase 3 trial for oral on-demand treatment in hereditary angioedema, evaluating a representative population. Safety and efficacy results were presented at the American Academy of Allergy, Asthma & Immunology annual meeting.

“Following self-administration, there was a reduction in the time to the beginning of symptom relief from a median of 6.7 hours with a placebo to 1.6 hours with a 300-mg dose of the plasma kallikrein inhibitor and 1.8 hours with a 600-mg dose,” Paul Audhya, MD, of developer KalVista Pharmaceuticals in Cambridge, Massachusetts, reported in the meeting.

According to findings presented during a late-breaking session, the KONFIDENT trial met key secondary endpoints, with both sebetralstat doses leading to faster reductions in attack severity and shorter times to complete resolution.

Hereditary angioedema is characterized by either a deficiency (type 1 HAE) or dysfunction (type II HAE) of the C1 inhibitor protein, resulting in tissue-swelling episodes that are often painful and sometimes dangerous when an attack affects a patient’s upper airway. Risk factors for attacks included infections and stress.

KalVista is seeking sebetralstat’s approval as the first oral, on-demand therapy for HAE and recently announced that it plans to submit a new drug application to the FDA this year. A host of drugs are approved for the condition as prophylaxis or on-demand treatment, including C1 esterase inhibitors and other plasma kallikrein inhibitors, however, the currently available on-demand options require subcutaneous or intravenous administration.

KONFIDENT is an international, randomized, double-blind, placebo-controlled, 3-way cross-over, phase 3 trial that included participants >_12 years, receiving on-demand therapy with or without long-term prophylaxis. They were randomized to treat <_3 attacks of any severity or location (except severe laryngeal) with 1-2 doses of sebetralstat 300 mg, 600 mg, or placebo.

The primary endpoint was time to the beginning of symptom relief (Patient Global Impression of Change rating of at least ‘‘A Little Better’’ two-time points in a row) within 12 hours.

The key secondary endpoints included time to first decrease in severity from attack onset (>_1 level decrease on Patient Global Impression of Severity [PGI-S] two-time points in a row) within 12 hours and time to attack resolution (PGI-S rating of ‘‘None’’) within 24 hours. Efficacy analyses were based on 252 attacks (84 attacks/treatment group).

After the screening, 136 participants were randomized; 110 experienced at least one attack during the trial, of whom 60% were women, and the median age was 40. Of the 264 total attacks, 87 occurred when patients were assigned to the 300-mg dose of sebetralstat, 93 while on the 600-mg dose, and 84 while assigned placebo.

Patients digitally documented their attacks, including the time of symptom onset and relief from their assigned treatments.

The key findings of the study were as follows:

  • A majority of attacks were treated within an hour of symptoms, and the most common primary attack locations were the abdomen (43%), arms/hands (29%), legs/feet (24%), and the head/face/neck (11%). Most were mild to moderate, while 17% were severe.
  • Second doses of a patient’s assigned medication were allowed 3 hours or more after the first dose if determined to be necessary by the patient. This occurred 38.4% of the time with the 300-mg dose of the study drug, 41.1% with the 600-mg dose, and 55.4% with the placebo.
  • · Treatment-related adverse events (AEs) with sebetralstat (2.3% with the 300-mg dose and 3.2% with the 600-mg dose) were comparable with placebo (4.8%), according to the researchers.
  • Serious treatment-emergent AEs occurred after one attack treated at the 300-mg sebetralstat dose (1.2%) and two attacks treated at the 600-mg dose (2.2%) versus none with placebo. One event at the 300-mg sebetralstat dose was severe.

However, the researchers acknowledged that most participants (92%) were white, which may hinder the general applicability of the findings. 

Source:

American Academy of Allergy, Asthma & Immunology annual meeting 

Powered by WPeMatico

Intravascular Imaging guided PCI Safer and more effective compared with angiography guidance

Previous studies have suggested that intravascular imaging-guided percutaneous coronary intervention (PCI) may reduce adverse events compared to angiography guidance alone. However, these studies lacked power to assess specific outcomes like all-cause death and myocardial infarction, and primarily used intravascular ultrasound rather than optical coherence tomography (OCT).

A recent systematic review and meta-analysis aimed to evaluate the comparative performance of intravascular imaging-guided PCI versus angiography-guided PCI, particularly with drug-eluting stents. This study was published in the journal Lancet by Prof. Gregg W Stone and colleagues.

The researchers conducted a comprehensive search of databases including MEDLINE, Embase, and Cochrane from inception to August 30, 2023, for randomized trials comparing intravascular imaging-guided PCI (intravascular ultrasound or OCT) with angiography-guided PCI. The primary endpoint was target lesion failure, including cardiac death, target vessel-myocardial infarction (TV-MI), or target lesion revascularization. Standard frequentist meta-analysis and network meta-analysis techniques were used to analyze direct and indirect data, respectively.

The key findings of the study were:

  • Twenty-two trials involving 15,964 patients were included, with a mean follow-up duration of 24.7 months.

  • Intravascular imaging-guided PCI demonstrated a decreased risk of target lesion failure compared to angiography-guided PCI (RR 0.71, 95% CI 0.63–0.80, p<0.0001).

  • This reduction was driven by decreased risks of cardiac death (RR 0.55, 95% CI 0.41–0.75, p=0.0001), TV-MI (RR 0.82, 95% CI 0.68–0.98, p=0.030), and target lesion revascularization (RR 0.72, 95% CI 0.60–0.86, p=0.0002).

  • Additionally, intravascular imaging guidance lowered the risks of stent thrombosis (RR 0.52, 95% CI 0.34–0.81, p=0.0036), all myocardial infarction (RR 0.83, 95% CI 0.71–0.99, p=0.033), and all-cause death (RR 0.75, 95% CI 0.60–0.93, p=0.0091).

  • Similar outcomes were observed for OCT-guided and intravascular ultrasound-guided PCI.

Intravascular imaging guidance, whether using OCT or intravascular ultrasound, improves both safety and effectiveness of PCI compared to angiography guidance alone. This approach reduces risks of death, myocardial infarction, repeat revascularization, and stent thrombosis, enhancing patient outcomes in coronary stent implantation procedures.

Reference:

Stone, G. W., Christiansen, E. H., Ali, Z. A., Andreasen, L. N., Maehara, A., Ahmad, Y., Landmesser, U., & Holm, N. R. Intravascular imaging-guided coronary drug-eluting stent implantation: an updated network meta-analysis. Lancet,2024. https://doi.org/10.1016/s0140-6736(23)02454-6

Powered by WPeMatico

Zirconia-based single-tooth restorations are reliable alternative materials to metal-based restorations with favourable outcomes

Zirconia-based single-tooth restorations are reliable alternative materials to metal-based restorations with favorable outcomes suggests a new study published in the Journal of Evidence-Based Dental Practice.

The primary aim was to investigate the survival rate of zirconia versus metal abutments, and the secondary aim was the clinical outcomes of all-ceramic versus metal-ceramic crowns on single-tooth implants. Patients with tooth agenesis who participated in a previously published prospective clinical study with a three-year follow-up were recalled after five years. Biological variables included survival and success rate of implants, marginal bone level, modified Plaque and Sulcus Bleeding Index and biological complications. Technical variables included restoration survival rate, marginal adaptation and technical complications. The aesthetic outcome of crowns and peri-implant mucosa in addition to patient-reported outcomes were recorded. Descriptive analysis, linear mixed model for quantitative data, or generalized linear mixed model for ordinal categorical data were applied; significance was set to 0.05.

Results: Fifty-three patients (mean age 32.4 years), with 89 implants participated in the 5-year examination. The implants supported 50 zirconia abutments with 50 all-ceramic (AC) crowns and 39 metal abutments with 29 metal-ceramic (MC) and 10 AC crowns. Zirconia-based single-tooth restorations are reliable alternative materials to metal-based restorations with favorable biological and aesthetic outcomes, and few technical complications.

Reference:

Mandana Hosseini, Nils Worsaae, Klaus Gotfredsen. The survival rate of implant-supported, single-tooth restorations based on zirconia or metal abutment in patients with tooth agenesis: A 5-year prospective clinical study. Journal of Evidence-Based Dental Practice. 2024,101970, ISSN 1532-3382. https://doi.org/10.1016/j.jebdp.2024.101970.(https://www.sciencedirect.com/science/article/pii/S1532338224000022)

Keywords:

Zirconia-based, single-tooth restorations, alternative materials, metal-based restorations, favourable outcomes, Journal of Evidence-Based Dental Practice, survival rate; dental implant; Single-Tooth; dental abutments; dental crowns; zirconium dioxide, Mandana Hosseini, Nils Worsaae, Klaus Gotfredsen

Powered by WPeMatico

Posttraumatic Epilepsy linked to increased risk of long-term Dementia: JAMA

A recent study published in the Journal of American Medical Association uncovered alarming connections between posttraumatic epilepsy (PTE) and long-term dementia risk. While both head injuries and epilepsy have long been associated with cognitive impairments, this study looked into the specific risk posed by PTE on dementia development over extended periods.

The study was conducted by the Atherosclerosis Risk in Communities (ARIC) project spanned over 25 years with data collected until December 31, 2019 and examined a cohort of 12,558 participants from four U.S. communities. The participants were initially enrolled in the late 1980s with data analysis carried out from March 2023 to January 2024. The findings highlighted the long-term consequences of head injuries and subsequent epileptic seizures.

The key findings from the study revealed that individuals with PTE underwent a 4.56 times higher risk of developing dementia when compared to the individuals without head injury or epilepsy. Even when compared to individuals with only head injuries or nontraumatic epilepsy, the dementia risk associated with PTE remained significantly high. These results underscore the critical need for preventative measures targeting head injuries and epilepsy, especially considering their potentially devastating cognitive outcomes.

The secondary analyses of the study indicated consistent dementia risk associated with PTE regardless of factors such as the severity of the initial head injury. These findings highlight the urgency for further research into the mechanisms underlying PTE and the identification of risk factors for its development.

The study emphasized the importance of these findings that provide compelling evidence linking PTE to long-term cognitive decline. This underlines the necessity for comprehensive strategies to prevent head injuries and subsequent epilepsy, as well as targeted interventions to reduce the risk of PTE-related dementia.

Reference:

Schneider, A. L. C., Law, C. A., Gottesman, R. F., Krauss, G., Huang, J., Kucharska-Newton, A., Jensen, F. E., Gugger, J. J., Diaz-Arrastia, R., & Johnson, E. L. (2024). Posttraumatic Epilepsy and Dementia Risk. In JAMA Neurology. American Medical Association (AMA). https://doi.org/10.1001/jamaneurol.2024.0010

Powered by WPeMatico

Exposure to air pollution during first three years of life linked with increased risk of childhood asthma: JAMA

USA: The cohort study of 5,279 children found that exposure to PM2.5 or NO2 air pollution during early childhood may lead to the development of childhood asthma. A higher risk was reported among minoritized families living in densely populated communities characterized by fewer resources and opportunities and multiple environmental coexposures.

“Mean nitrogen dioxide (NO2) and mean fine particulate matter (PM2.5) air pollution during the first three years of life were linked with asthma incidence by early and middle childhood, after adjusting for individual-level characteristics,” the researchers reported in their study published in JAMA Network Open.

The association of ambient pollution (NO2 or PM2.5) with incident asthma was modified by individual-level and community-level socioeconomic circumstances, including maternal education and race.

Air pollution is a near-ubiquitous exposure and contributes largely to disease and premature death in the world, including for children. Air pollution exposure has been consistently linked with respiratory morbidity, including exacerbation of asthma and wheezing in children. Various reviews on air pollution, asthma, and respiratory symptoms in children concluded that outdoor traffic pollution contributes to childhood asthma development. However, many studies lack the racial and ethnic, geographic, and socioeconomic diversity to evaluate susceptibility by individual-level and community-level contextual factors.

Against the above background, Antonella Zanobetti, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, and colleagues aimed to examine early life exposure to PM2.5 and NO2 air pollution and asthma risk by early and middle childhood. They also determined whether individual and community-level characteristics modify associations between air pollution exposure and asthma.

For this purpose, the researchers included children enrolled in cohorts participating in the Children’s Respiratory and Environmental Workgroup consortium. The location of the birth cohorts was throughout the US, recruited between 1987 and 2007, and followed up through 11 years.

The survival analysis was adjusted for parental asthma, mother’s education, child’s race and ethnicity, smoking during pregnancy, sex, neighbourhood characteristics, and cohort. Statistical analysis was performed from February 2022 to December 2023.

The study’s main outcomes were caregiver reports of physician-diagnosed asthma through early (age 4 years) and middle (age 11 years) childhood.

The study led to the following findings:

  • Among 5279 included children, 51.5% were male; 24.7% of children had asthma by 11 years of age, and 18.1% had asthma by 4 years of age.
  • Mean values of pollutants over the first 3 years of life were associated with asthma incidence.
  • A 1 IQR increase in NO2 (6.1 μg/m3) was associated with increased asthma incidence among children younger than 5 years (HR, 1.25) and children younger than 11 years (HR, 1.22).
  • A 1 IQR increase in PM2.5 (3.4 μg/m3) was associated with increased asthma incidence among children younger than 5 years (HR, 1.31) and children younger than 11 years (OR, 1.23).
  • Associations of PM2.5 or NO2 with asthma were increased when mothers had less than a high school diploma, among Black children, in communities with fewer child opportunities, and in census tracts with a higher percentage of Black population and population density; for example, there was a significantly higher association between PM2.5 and asthma incidence by younger than 5 years of age in Black children (HR, 1.60) compared with White children (HR, 1.17).

“Air pollution continues to be a global burden with adverse consequences on childhood health,” the researchers wrote.

“Lowering asthma risk in the US requires reduction and regulation of air pollution combined with the creation of greater educational, environmental, and health equity at a community level,” they concluded.

Reference:

Zanobetti A, Ryan PH, Coull BA, et al. Early-Life Exposure to Air Pollution and Childhood Asthma Cumulative Incidence in the ECHO CREW Consortium. JAMA Netw Open. 2024;7(2):e240535. doi:10.1001/jamanetworkopen.2024.0535

Powered by WPeMatico

Vitamin E Intake Reduces Risk of Non-Alcoholic Fatty Liver Disease:Study

Non-alcoholic fatty liver disease (NAFLD) has emerged as a prevalent chronic liver disorder with its severe manifestation which is often linked to oxidative stress. A recent study published in the Nature Scientific Reports uncovered promising evidence of the protective potential of Vitamin E against NAFLD.

This study utilized data from the National Health and Nutrition Examination Survey (2017–2020) to analyze the relationship between various forms of Vitamin E intake and the prevalence of NAFLD. The study focused on the dietary intake, supplementary use and total consumption of Vitamin E which found compelling associations with hepatic steatosis and NAFLD. This investigation included a total of 6122 participants and utilized liver ultrasound transient elastography to measure hepatic steatosis that represented as controlled attenuated parameter (CAP) scores. The diagnosis of NAFLD was based on specific CAP threshold values.

After meticulous adjustments for several covariates including demographics, lifestyle factors and medical conditions, this study unearthed significant inverse correlations between Vitamin E intake and NAFLD. The dietary Vitamin E intake demonstrated a robust protective effect against NAFLD with higher intake levels associated with reduced odds of the disease. Also, supplementary Vitamin E use expressed a notable inverse association with NAFLD prevalence, further suggesting its potential in reducing liver disease risk.

The findings also shed light on the importance of total Vitamin E intake by encompassing both dietary and supplemental forms in conferring protection against NAFLD. While the results showed a marginal improvement, it highlights the overall beneficial impact of Vitamin E on liver health. Also, the study highlighted variations in the protective effects of Vitamin E based on the presence of hyperlipidemia that suggests tailored approaches for different risk profiles. 

Reference:

Qi, X., Guo, J., Li, Y., Fang, C., Lin, J., Chen, X., & Jia, J. (2024). Vitamin E intake is inversely associated with NAFLD measured by liver ultrasound transient elastography. In Scientific Reports (Vol. 14, Issue 1). Springer Science and Business Media LLC. https://doi.org/10.1038/s41598-024-52482-w

Powered by WPeMatico

COVID-19 vaccination linked to persistence of long-term health risks of COVID infection: Study

A recent study highlights the persistent risk of long-term health consequences following SARS-CoV-2 infection and the protective effects of COVID-19 vaccination. The findings were published in the recent edition of the Nature Communications journal that provide crucial insights into the ongoing pandemic.

This retrospective cohort study was conducted in Hong Kong analyzed data from a territory-wide public healthcare database and encompassed a total of 1,175,277 patients with SARS-CoV-2 infection. This research stratified individuals by their vaccination status and compared them to non-infected controls. Over the course of one year, this study meticulously evaluated the risk of clinical sequelae, cardiovascular complications and all-cause mortality.

The results revealed a progressive reduction in the risk of all-cause mortality among the patients with SARS-CoV-2 infection when compared to the control group. The patients who were fully vaccinated or had received booster doses expressed a notably lower risk of experiencing major cardiovascular diseases and all-cause mortality when compared to those who were unvaccinated or partially vaccinated. This protective effect was particularly evident within the first 30-90 days post-infection.

The individuals who had completed their vaccination series or received booster doses did not face a significant increase in health risks from 271 and 91 days after infection, respectively. On the contrary, the individuals who remained unvaccinated or incompletely vaccinated continued to endure a heightened risk of clinical sequelae for up to a year following SARS-CoV-2 infection. This real-world evidence highlights the effectiveness of COVID-19 vaccines in reducing the long-term health consequences of SARS-CoV-2 infection and its persistence.

Reference:

Lam, I. C. H., Zhang, R., Man, K. K. C., Wong, C. K. H., Chui, C. S. L., Lai, F. T. T., Li, X., Chan, E. W. Y., Lau, C. S., Wong, I. C. K., & Wan, E. Y. F. (2024). Persistence in risk and effect of COVID-19 vaccination on long-term health consequences after SARS-CoV-2 infection. In Nature Communications (Vol. 15, Issue 1). Springer Science and Business Media LLC. https://doi.org/10.1038/s41467-024-45953-1

Powered by WPeMatico

Collagen patch cover applied to anastomotic site after laparoscopic colectomy may facilitate recovery of bowel function: Study

Collagen patch cover applied to anastomotic site after laparoscopic colectomy may facilitate recovery of bowel function suggests a new study published in the BMC Surgery.

Numerous factors can influence bowel movement recovery and anastomotic healing in colorectal surgery, and poor healing can lead to severe complications and increased medical expenses. Collagen patch cover (CPC) is a promising biomaterial that has been demonstrated to be safe in animal models and has been successfully applied in various surgical procedures in humans. This study. A retrospective review of medical records from July 2020 to June 2022 was conducted to identify consecutive patients who underwent laparoscopic colectomy. Patients who received CPC at the anastomotic site were assigned to the collagen group, whereas those who did not receive CPC were assigned to the control group. Results: Data from 241 patients (collagen group, 109; control group, 132) were analyzed. Relative to the control group, the collagen group exhibited a faster recovery of bowel function, including an earlier onset of first flatus (2.93 days vs. 3.43 days, p < 0.01), first defecation (3.73 days vs. 4.18 days, p = 0.01), and oral intake (4.30 days vs. 4.68 days, p = 0.04). CPC use was also associated with lower use of postoperative intravenous analgesics. The complication rates in the two groups did not differ significantly. CPCs can be safely and easily applied to the anastomotic site during laparoscopic colectomy, and can accelerate bowel movement recovery. Further studies on the effectiveness of CPCs in colorectal surgery involving larger sample sizes are required.

Reference:

Huang, PY., Tsai, MC., Kiu, KT. et al. Collagen patch cover facilitates recovery of bowel function after laparoscopic colectomy. BMC Surg 24, 66 (2024). https://doi.org/10.1186/s12893-024-02339-w

Keywords:

Collagen patch, cover, anastomotic site, laparoscopic colectomy, recovery, bowel function, BMC Surgery, Huang, PY., Tsai, MC., Kiu, K

Powered by WPeMatico